BioSpace News Archive

Drug Development

Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration

Capsida Biotherapeutics announced new preclinical data that demonstrate the potential of its next-generation intravenously administered gene therapy candidate, CAP-003, to safely and effectively treat Parkinson’s disease associated with GBA mutations.

May 10, 2024
·
4 min read
Genetown

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, revealed significant growth in the CENTOGENE Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases.

May 10, 2024
·
6 min read
Pharm Country

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, announces that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, will be attending the EF Hutton Annual Global Conference, which will be held at The Plaza Hotel in New York, NY on Wednesday, May 15, 2024.

May 10, 2024
·
8 min read
Pharm Country

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc. announced longer-term data updates from its lentiviral vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy.

May 10, 2024
·
16 min read
Drug Development

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US.

May 10, 2024
·
7 min read
Business

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

May 10, 2024
·
6 min read
Drug Development

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine, Inc., a clinical-stage gene editing company, announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines.

May 10, 2024
·
5 min read
Ribobay Pharma boosts CRDMO offerings with Cytiva’s first FlexFactory platform for oligonucleotides

Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization and a spin-off company of General Biol Co., Ltd, will provide cGMP-level oligonucleotide CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing.

May 10, 2024
·
3 min read
Business

ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance

ANI Pharmaceuticals, Inc. announced financial results and business highlights for the three months ended March 31, 2024.

May 10, 2024
·
22 min read
Drug Development

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced the presentation of preclinical data supporting lead program AXV-101, which is being developed to address blindness and obesity associated with Bardet-Biedl Syndrome.

May 10, 2024
·
4 min read